Dfn-15
Osteoarthritis
Sunnybrook Health Sciences CentrePhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 46/ 100
- Competitive Position
- 89/ 100
Competitive context
15 Active assets in the Osteoarthritis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Naltrexone Brigham and Women's Hospital | Phase 4 | BBB |
Buprenorphine Mundipharma Pte Ltd. | Phase 4 | BBB |
Oxycodone Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 4 | BBB |
FENTANYL Janssen Pharmaceutica | Phase 4 | BBB |
Duloxetine The Catholic University of Korea | Phase 4 | BBB |
View all 48 →
Same molecule, other indications
Dfn-15 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →